Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Investigators evaluated stromal content in the tumor microenvironment as a marker for bladder cancer prognosis, including disease-free survival and overall survival.

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Immunocompromised patients with bladder cancer who undergo TURBT followed by BCG immunotherapy have worse survival outcomes compared to non-immunocompromised patients, a study suggests.

Today’s ACT Brief highlights how artificial intelligence is transforming trial data management, why biotechs are embracing parallel execution to accelerate development, and new Phase III results ...

Stage 0 cancer, known as carcinoma in situ, marks the earliest stage of cancer development. Abnormal cells are present but ...

Stage 0 cancer, or carcinoma in situ, represents the earliest detectable phase where abnormal cells are confined to their ...

Deion Sanders shared his cancer-free journey and listened to survivors' stories at UCHealth Longs Peak Medical Center.